Inhibikase Therapeutics, Inc. Quarterly Marketable Securities, Current in USD from Q4 2021 to Q2 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of investment in marketable security, classified as current.
Summary: Inhibikase Therapeutics, Inc. quarterly Marketable Securities, Current history and growth rate from Q4 2021 to Q2 2024.
Inhibikase Therapeutics, Inc. Marketable Securities, Current for the quarter ending June 30, 2024 was $4.85M, a 74.5% decline year-over-year.

Marketable Securities, Current, Quarterly (USD)

Marketable Securities, Current, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date	Report	Filed
Q2 2024	$4.85M	-$14.2M	-74.5%	Jun 30, 2024	10-Q	2024-08-14
Q1 2024	$7.4M	-$14.4M	-66%	Mar 31, 2024	10-Q	2024-05-15
Q4 2023	$4.09M	-$11.8M	-74.2%	Dec 31, 2023	10-Q	2024-08-14
Q3 2023	$1.97M	-$18.8M	-90.5%	Sep 30, 2023	10-Q	2023-11-14
Q2 2023	$19M			Jun 30, 2023	10-Q	2023-08-14
Q1 2023	$21.8M			Mar 31, 2023	10-Q	2023-05-15
Q4 2022	$15.9M	+$15.9M		Dec 31, 2022	10-K	2024-03-27
Q3 2022	$20.8M			Sep 30, 2022	10-Q	2022-11-14
Q4 2021	$0			Dec 31, 2021	10-K	2023-03-31

* An asterisk sign (*) next to the value indicates that the value is likely invalid.